A Phase I Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LTC004 in Patients With Advanced or Metastatic Malignancies
Latest Information Update: 03 Jul 2024
At a glance
- Drugs LTC-004 (Primary)
- Indications Adenocarcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Lymphoma; Malignant thymoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Leto Laboratories
Most Recent Events
- 04 Jun 2024 Results of dose-escalation part presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jan 2023 New trial record